Instrument Inactif

Autres langues Kuros Biosciences AG Swiss Exchange

Actions

CH0011025217

Recherche biotechnologique et médicale

Cours en clôture Swiss Exchange
- ^CHF	-

14/08	Transcript : Kuros Biosciences AG, H1 2026 Earnings Call, Aug 13, 2026
13/08	Bourse Zurich: les indices en vert, investisseurs rassurés par l'inflation US	AW

Autres langues

13/08	Kuros Biosciences AG Reports Earnings Results for the Half Year Ended June 30, 2026
13/08	Kuros Biosciences Swings to Profit in H1; Revenue Up
13/08	Kuros bestätigt nach starkem ersten Halbjahr Jahresziele
13/08	Kuros Biosciences Swings to Profit in H1; Revenue Up
13/08	Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability
13/08	Kuros Biosciences Ag Confirms Earnings Guidance for the Year 2026 and 2028
08/07	Analystenempfehlungen: Amrize, Daimler Truck, DHL, UBS, Apple, Cloudflare, Qualcomm…
08/07	Morning Meeting: Die Letzten werden die Ersten sein
17/06	Kuros stellt weitere MagnetOs-Strategie am Kapitalmarkttag vor
17/06	Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich
07/05	Kuros Biosciences Names New COO
07/05	Kuros ernennt I.V. Hall zum neuen Chief Operating Officer
07/05	Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
07/05	Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
07/05	Kuros Biosciences Announces Executive Changes
15/04	Annual General Meeting of Kuros Biosciences approves all resolutions
14/04	Kuros mit klarem Umsatzplus im ersten Quartal
14/04	Kuros Biosciences Logs Higher Q1 Sales
14/04	Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
10/03	Aktien Schweiz freundlich - Novartis und Nestle bremsen
10/03	Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028
10/03	Kuros schreibt 2025 schwarze Zahlen
10/03	Kuros Biosciences Swings to FY25 Profit; Revenue Rises
10/03	Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025
10/03	Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2025